Cargando…

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is standard therapy for head and neck squamous cell carcinoma (HNSCC). However, most HNSCC tumors are resistant to it and require alternative treatments. Here, we explored the mechanism of cetuximab resistance and evaluated its clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yonesaka, Kimio, Tanaka, Kaoru, Kitano, Mutsukazu, Kawakami, Hisato, Hayashi, Hidetoshi, Takeda, Masayuki, Sakai, Kazuko, Nishio, Kazuto, Doi, Katsumi, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769016/ https://www.ncbi.nlm.nih.gov/pubmed/31570699 http://dx.doi.org/10.1038/s41389-019-0164-9

Ejemplares similares

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
por: Nonagase, Yoshikane, et al.
Publicado: (2019)

Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study
por: Kurosaki, Takashi, et al.
Publicado: (2020)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma
por: Kawakami, Hisato, et al.
Publicado: (2013)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

EGFR-TKI不良反应管理专家共识
Publicado: (2019)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
por: Goto, Yasushi, et al.
Publicado: (2017)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
por: Wu, Jing-Xun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qdo963id82emkkfs9k0m06f87h